Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVExtend

OBJECTIVE: Fracture risk increases with age, but few studies focus on persons ≥80 years. In the ACTIVE trial, treatment with abaloparatide for 18 months reduced osteoporotic fracture risk and increased bone mineral density. These effects were maintained with 24 months alendronate treatment in ACTIVE...

Descripción completa

Detalles Bibliográficos
Autores principales: Greenspan, Susan L., Fitzpatrick, Lorraine A., Mitlak, Bruce, Wang, Yamei, Harvey, Nicholas C., Deal, Chad, Cosman, Felicia, McClung, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Original Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7515468/
https://www.ncbi.nlm.nih.gov/pubmed/32665529
http://dx.doi.org/10.1097/GME.0000000000001593

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7515468/
https://www.ncbi.nlm.nih.gov/pubmed/32665529
http://dx.doi.org/10.1097/GME.0000000000001593

Ejemplares similares